Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Monge, Susana ^a   Guillot, Vicente ^b   Alvarez, Marta ^b   Chueca, Natalia ^b   Stella, Natalia ^c   Pena, Alejandro ^b   Delgado, Rafael ^d   Córdoba, Juan ^e   Aguilera, Antonio ^f   Vidal, Carmen ^g   García, Federico ^b  

^a CARLOS III INSTITUTE OF HEALTH   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f University Hospital of Santiago de Compostela   (Spain)

^g HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ALGORITHM; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; COHORT ANALYSIS; DRUG SCREENING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PREVALENCE; PROSPECTIVE STUDY; SPAIN; WORLD HEALTH ORGANIZATION; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MULTICENTER STUDY; MUTATION; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; VIRAL LOAD; YOUNG ADULT;

EID: 84898603227     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090710     Document Type: Article

References (24)

1. Wittkop L, Gǔnthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, et al. (2011) Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 11: 363-371.
2. Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA 3rd, et al. (2008) Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 197: 867-870. (Pubitemid 351417010)
3. European AIDS clinical Society. EACS Guidelines v6.1. Available: http://www. europeanaidsclinicalsociety.org. Accessed: 12 Nov 2012.
4. Office of AIDS Research Advisory Council (OARAC). Bethesda (US). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available: http://www.aidsinfo.nih.gov/. Accessed: 28 Mar 2012.
5. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, et al. (2012) Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society-USA Panel. JAMA 308: 387-402.
6. Grupo de Estudio de SIDA. Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualizacio'n enero 2013). Available: http://www.gesida-seimc.org. Accessed: 6 Mar 2013.
7. Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, et al. (2005) Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 41: 1316-1323. (Pubitemid 41532676)
8. Caro-Murillo AM, Castilla J, Pérez-Hoyos S, Miró JM, Podzamczer D, et al. (2007) Spanish cohort of nai?ve human immunodeficiency virus infected patients (CoRIS): rationale, organization and initial results. Enferm Infecc Microbiol Clin 25: 23-31. (Pubitemid 46232687)
9. Sobrino-Vegas P, Gutiérrez F, Berenguer J, Labarga P, García F, et al. (2011) The cohort of the spanish hiv research network (coris) and its associated biobank; organizational issues, main findings and losses to follow-up. Enferm Infecc Microbiol Clin 29: 645-653.
10. García F, Pérez-Cachafeiro S, Guillot V, Alvarez M, Pérez-Romero P, et al. (2011) Transmission of HIV drug resistance and non-B subtype distribution in the Spanish cohort of antiretroviral treatment nai?ve HIV-infected individuals (CoRIS). Antivir Res 91: 150-153.
11. Monge S, Guillot V, Alvarez M, Penâ A, Viciana P, et al. (2012) Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class, Clin Microbiol Infect 18: E485-490.
12. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug resistance mutations for surveillance of transmitted human immunodeficiency virus type 1 drug-resistance: 2009 update. PloS One 4: e4724.
13. Karlsson A, Bjǒrkman P, Bratt G, Ekvall H, Gissle'n M, et al. (2012) Low prevalence of transmitted drug resistance in patients newlydiagnosed with HIV-1 infection in Sweden 2003-2010. PLoS One 7: e33484.
14. De Gascun CF, Waters A, Regan C, O'Halloran J, Farrell G, et al. (2012) Documented Prevalence of HIV Type 1 Antiretroviral Transmitted Drug Resistance in Ireland from 2004 to 2008. AIDS Res Hum Retroviruses 28: 276-281.
15. Dolling D, Sabin C, Delpech V, Smit E, Pozniak A, et al. (2012) Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ 345: e5253.
16. Descamps D, Chaix ML, Montes B, Pakianather S, Charpentier C, et al. (2010) Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother 65: 2620-2627.
17. Liu TF, Shafer RW (2006) Web Resources for HIV type 1 Genotypic-Resistance Test Interpretation. Clin Infect Dis 42: 1608-1618.
18. Bartmeyer B, Kuecherer C, Houareau C, Werning J, Keeren K, et al. (2010) Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS One 5: e12718.
19. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, et al. (2009) Transmission of drug-resistant human immunodeficiency virus type 1 is stabilizing in Europe. J Infect Dis 200: 1503-1508.
20. Hurt CB, McCoy SI, Kuruc J, Nelson JA, Kerkau M, et al. (2009) Transmitted antiretroviral drug resistance among acute and recent human immunodeficiency virus infections in North Carolina from 1998 to 2007. Antivir Ther 14: 673-678.
21. Price MA, Wallis CL, Lakhi S, Karita E, Kamali A, et al. (2011) Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses 27: 5-12.
22. Frentz D, van de Vijver DA, Boucher CA Albert J (2011) Estimates of HIV transmitted drug resistance can be inflated due to natural sequence polymorphisms. J Acquir Immune Defic Syndr 58: e135-137.
23. Beerenwinkel N, Dǎumer M, Sing T, Rahnenfuhrer J, Lengauer T, et al. (2005) Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. J Infect Dis 191: 1953-1960. (Pubitemid 40705404)
24. Li JZ, Paredes R, Ribaudo HJ, Kozal MJ, Svarovskaia ES, et al. (2013) Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J Infect Dis 207: 893-897.